Publications

Lee DJ, Cha EK, Dubin JM, Beltran H, Chromecki TF, Fajkovic H, Scherr DS, Tagawa ST, Shariat SF.  2012.  Novel therapeutics for the management of castration-resistant prostate cancer (CRPC).. BJU Int. 109(7):968-85.

Tagawa ST, Beltran H.  2011.  Abiraterone plus prednisone improves survival in metastatic castration-resistant prostate cancer.. Asian J Androl. 13(6):785-6.

Beltran H, Rickman DS, Park K, Chae SS, Sboner A, MacDonald TY, Wang Y, Sheikh KL, Terry S, Tagawa ST et al..  2011.  Molecular characterization of neuroendocrine prostate cancer and identification of new drug targets.. Cancer Discovery. 1(6):487-95.

Beltran H, Beer TM, Carducci MA, de Bono J, Gleave M, Hussain M, Kelly WK, Saad F, Sternberg C, Tagawa ST et al..  2011.  New therapies for castration-resistant prostate cancer: efficacy and safety.. Eur Urol. 60(2):279-90.